- Lexaria continues to create a strong, revenue-generating business model to support its growing patent portfolio
- The company out-licenses disruptive delivery technology, giving licensees access to existing patents
- Lexaria entered into a new beverage license agreement with a California-based cannabis firm
- The company recently announced four new appointments to its scientific advisory board
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a drug-delivery platform innovator with existing cannabinoid licensing agreements in Canada and the United States, as well as internationally. By out-licensing disruptive delivery technology DehydraTECH, the company has created a strong, revenue-generating business model and a growing patent portfolio.
At the end of 2018, LXRP held 10 granted patents, with 53 patent applications filed and pending in more than 40 countries around the world. The company is unique in that it is the only global company with patents issued for the oral delivery of all cannabinoids. DehydraTECH has patents for cannabidiol (CBD), all other non-psychoactive cannabinoids, other psychoactive compounds, fat-soluble vitamins, NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen), nicotine and other molecules.
Lexaria out-licenses DehydraTECH, giving licensees access to its many existing patents. These patents include combinations of ready-to-drink beverages, wine, coffee, tea, sports drinks, supplements and more. Third-party partners and start-up businesses are currently paying royalties for cannabinoid licensing agreements, and a Fortune 100 company has licensed Lexaria’s technology for oral nicotine delivery in the U.S.
The company continues to grow additional revenue streams. On April 24, 2019, Lexaria announced (http://ibn.fm/6cRnl) its entry into a new beverage license agreement with a private California-based cannabis company. The financial terms of the definitive five-year agreement were not disclosed. LXRP’s patented DehydraTECH technology will be used by the private company in producing and selling cannabis-based beverages in California and Nevada. Last year, Lexaria announced that a Canadian company had licensed its technology to produce cannabis beverages in Canada.
DehydraTECH is unique in that it promotes healthier ingestion methods. The technology improves taste, rapidity and delivery of bioactive compounds while removing odor. This allows cannabinoids and other bioactive compounds to be delivered in high-quality food products and beverages without the need for additional sugars. It also provides a safer means of ingestion than the more traditional method of smoking.
In addition, Lexaria continues to strengthen its scientific research and product development team and has appointed four new members to its scientific advisory board. “Lexaria is building towards becoming one of the world’s leaders in drug-delivery technology, and our most recent advisors can assist in achieving that goal,” Lexaria CEO Chris Bunka stated in a news release.
To learn more about the background, interests and expertise that each new appointment brings to the company, read the announcement at http://ibn.fm/LwZ8R. These new board members will be providing critical scientific guidance to the company’s ongoing and future research and development programs.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
